CY1119648T1 - Αλατα και κρυσταλλικες μορφες παραγοντα που προκαλει αποπτωση - Google Patents
Αλατα και κρυσταλλικες μορφες παραγοντα που προκαλει αποπτωσηInfo
- Publication number
- CY1119648T1 CY1119648T1 CY20171101210T CY171101210T CY1119648T1 CY 1119648 T1 CY1119648 T1 CY 1119648T1 CY 20171101210 T CY20171101210 T CY 20171101210T CY 171101210 T CY171101210 T CY 171101210T CY 1119648 T1 CY1119648 T1 CY 1119648T1
- Authority
- CY
- Cyprus
- Prior art keywords
- salts
- formats
- crystal
- crystal formats
- dimethylcyclohex
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41665610P | 2010-11-23 | 2010-11-23 | |
| PCT/US2011/061678 WO2012071336A1 (en) | 2010-11-23 | 2011-11-21 | Salts and crystalline forms of an apoptosis-inducing agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119648T1 true CY1119648T1 (el) | 2018-04-04 |
Family
ID=45094808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101210T CY1119648T1 (el) | 2010-11-23 | 2017-11-17 | Αλατα και κρυσταλλικες μορφες παραγοντα που προκαλει αποπτωση |
Country Status (27)
| Country | Link |
|---|---|
| US (10) | US8722657B2 (https=) |
| EP (1) | EP2643322B1 (https=) |
| JP (1) | JP6141188B2 (https=) |
| KR (1) | KR101923364B1 (https=) |
| CN (2) | CN107266435A (https=) |
| AU (1) | AU2011332043C1 (https=) |
| BR (1) | BR112013012740A2 (https=) |
| CA (1) | CA2817629C (https=) |
| CY (1) | CY1119648T1 (https=) |
| DK (1) | DK2643322T3 (https=) |
| ES (1) | ES2644230T3 (https=) |
| HR (1) | HRP20171754T1 (https=) |
| HU (1) | HUE034804T2 (https=) |
| IL (1) | IL226489B (https=) |
| LT (1) | LT2643322T (https=) |
| MX (1) | MX343014B (https=) |
| NO (1) | NO2643322T3 (https=) |
| NZ (1) | NZ610151A (https=) |
| PL (1) | PL2643322T3 (https=) |
| PT (1) | PT2643322T (https=) |
| RS (1) | RS56697B1 (https=) |
| RU (1) | RU2628560C2 (https=) |
| SG (1) | SG190361A1 (https=) |
| SI (1) | SI2643322T1 (https=) |
| TW (1) | TWI526443B (https=) |
| WO (1) | WO2012071336A1 (https=) |
| ZA (1) | ZA201303586B (https=) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| CA3152557A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| PT2643322T (pt) | 2010-11-23 | 2017-11-13 | Abbvie Inc | Sais e formas cristalinas de um agente indutor de apoptose |
| TWI620736B (zh) | 2010-11-23 | 2018-04-11 | 艾伯維巴哈馬有限公司 | 使用選擇性ｂｃｌ-２抑制劑之治療方法 |
| CN104768581A (zh) | 2012-09-07 | 2015-07-08 | 吉宁特有限公司 | II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗 |
| UY39848A (es) | 2013-03-13 | 2022-09-30 | Abbvie Ireland Unlimited Co | Procesos para la preparación de un agente inductor de la apoptosis |
| AR095265A1 (es) | 2013-03-13 | 2015-09-30 | Abbvie Inc | Procesos para la preparación de un agente inductor de la apoptosis |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EA029281B1 (ru) | 2013-07-30 | 2018-03-30 | Джилид Коннектикут, Инк. | Полиморф ингибиторов syk |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| SI3060551T1 (sl) | 2013-10-22 | 2019-11-29 | Chiesi Farm Spa | Postopek za pripravo inhibitorja PDE4 |
| EP3077401B1 (en) | 2013-12-06 | 2018-04-18 | Genentech, Inc. | Serine/threonine kinase inhibitors |
| TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
| US9238652B2 (en) | 2014-03-04 | 2016-01-19 | Abbvie Inc. | Processes for the preparation of an apoptosis-inducing agent |
| BR112016028641A2 (pt) | 2014-07-14 | 2017-08-22 | Gilead Sciences Inc | ?método para tratar câncer? |
| MA40596B1 (fr) | 2014-08-11 | 2021-12-31 | Acerta Pharma Bv | Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2 |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| KR20240129101A (ko) * | 2015-07-07 | 2024-08-27 | 제넨테크, 인크. | 항-her2 항체-약물 접합체 및 bcl-2 억제제를 사용한 병용 요법 |
| WO2017063572A1 (zh) * | 2015-10-13 | 2017-04-20 | 苏州晶云药物科技有限公司 | 细胞凋亡诱导剂的新晶型及其制备方法 |
| AU2016349279A1 (en) | 2015-11-03 | 2018-05-10 | Board Of Regents, The University Of Texas System | Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer |
| AU2016363005A1 (en) | 2015-12-04 | 2018-07-05 | Portola Pharmaceuticals, Inc. | Cerdulatinib for treating hematological cancers |
| EP3426655A1 (en) | 2016-03-10 | 2019-01-16 | Assia Chemical Industries Ltd. | Solid state forms of venetoclax and processes for preparation of venetoclax |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| CN109563096A (zh) * | 2016-06-09 | 2019-04-02 | 雷迪博士实验室有限公司 | 固体形式的维奈托克和用于制备维奈托克的方法 |
| KR102376764B1 (ko) | 2016-08-05 | 2022-03-18 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물 |
| US10759798B2 (en) * | 2016-09-14 | 2020-09-01 | Hangzhou Solipharma Co., Ltd. | ABT-199 addition salt and crystal form thereof, preparation method thereof, and pharmaceutical composition thereof |
| US10800777B2 (en) | 2016-10-14 | 2020-10-13 | Mylan Laboratories Limited | Polymorphic forms of VENCLEXTA |
| US20180133212A1 (en) | 2016-11-03 | 2018-05-17 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
| EP3333167A1 (en) | 2016-12-09 | 2018-06-13 | LEK Pharmaceuticals d.d. | Solid forms of venetoclax |
| WO2018157803A1 (zh) * | 2017-02-28 | 2018-09-07 | 苏州科睿思制药有限公司 | 维奈妥拉的晶型及其制备方法 |
| WO2018167652A1 (en) * | 2017-03-13 | 2018-09-20 | Laurus Labs Limited | Process for preparation of amorphous form of venetoclax |
| CN107089981A (zh) * | 2017-04-24 | 2017-08-25 | 杭州科耀医药科技有限公司 | 一种BCL‑2抑制剂Venetoclax的合成方法 |
| WO2018225043A1 (en) * | 2017-06-10 | 2018-12-13 | Lupin Limited | Solid state forms of an apoptosis-inducing agent and processes thereof |
| CN110759908B (zh) * | 2017-06-26 | 2021-03-12 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用 |
| AU2018322059C1 (en) | 2017-08-23 | 2024-09-12 | Guangzhou Lupeng Pharmaceutical Company Ltd. | BCL-2 inhibitors |
| CA3073871A1 (en) | 2017-08-25 | 2019-02-28 | Gilead Sciences, Inc. | Polymorphs of syk inhibitors |
| WO2019135253A1 (en) * | 2018-01-02 | 2019-07-11 | Mylan Laboratories Limited | Polymorphic forms of venetoclax |
| IT201800003284A1 (it) * | 2018-03-05 | 2019-09-05 | Olon Spa | Forme cristalline di venetoclax |
| EP3788035B1 (en) | 2018-05-04 | 2024-08-07 | Alexion Pharmaceuticals, Inc. | Solid forms of cerdulatinib |
| CN108997333A (zh) * | 2018-07-04 | 2018-12-14 | 江苏中邦制药有限公司 | 一种b细胞淋巴瘤因子-2抑制剂abt-199的制备方法 |
| WO2020023435A1 (en) | 2018-07-24 | 2020-01-30 | Albany Molecular Research, Inc. | Venetoclax basic salts and processes for the purification of venetoclax |
| CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| CA3094449C (en) | 2018-07-31 | 2023-02-28 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases |
| JP2021516262A (ja) | 2018-07-31 | 2021-07-01 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | リツキシマブ及び／若しくはベンダムスチンと組み合わされたＢｃｌ−２阻害剤又はＣＨＯＰと組み合わされたＢｃｌ−２阻害剤の相乗的な抗腫瘍効果 |
| TWI725488B (zh) | 2018-07-31 | 2021-04-21 | 大陸商蘇州亞盛藥業有限公司 | Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途 |
| US12220419B2 (en) | 2018-08-22 | 2025-02-11 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| TWI848030B (zh) | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| CN113950479A (zh) | 2019-02-22 | 2022-01-18 | 克洛诺斯生物股份有限公司 | 作为syk抑制剂的缩合吡嗪的固体形式 |
| GB201911627D0 (en) * | 2019-08-14 | 2019-09-25 | Johnson Matthey Plc | Polymorph of venetoclax and method for preparing the polymorph |
| US12552784B2 (en) | 2019-12-27 | 2026-02-17 | Newave Pharmaceutical Inc. | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| WO2021207581A1 (en) | 2020-04-10 | 2021-10-14 | Abbvie Inc. | Crystalline forms of an apoptosis-inducing agent |
| CN115916822A (zh) | 2020-04-24 | 2023-04-04 | 基因泰克公司 | 使用抗CD79b免疫缀合物的方法 |
| CN114073703B (zh) * | 2020-08-21 | 2022-12-30 | 苏州亚盛药业有限公司 | 用于治疗非酒精性脂肪肝炎的组合物和方法 |
| WO2022043538A1 (en) | 2020-08-29 | 2022-03-03 | argenx BV | Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor |
| US20250319183A1 (en) | 2021-04-07 | 2025-10-16 | David Avigan | Compositions and methods for the treatment of cancer |
| IT202100025976A1 (it) | 2021-10-06 | 2023-04-06 | Univ Degli Studi Di Perugia | Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1) |
| AR134497A1 (es) | 2023-11-28 | 2026-01-21 | Sanofi Sa | Combiterapia multifuncional con activador de los linfocitos citolíticos naturales (nk) para tratar trastornos neoplásicos hemáticos |
| CN117599041B (zh) * | 2024-01-22 | 2024-05-03 | 中国人民解放军军事科学院军事医学研究院 | 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| PT1019385E (pt) | 1995-09-15 | 2004-06-30 | Upjohn Co | N-oxidos de aminoaril-oxazolidinona |
| DK0929578T3 (da) | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| WO2000001389A1 (en) | 1998-07-06 | 2000-01-13 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| DE19913692A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
| DE19929361A1 (de) | 1999-06-25 | 2001-01-04 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
| US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| ATE305302T1 (de) | 1999-12-28 | 2005-10-15 | Eisai Co Ltd | Heterozyklische verbindungen mit sulfonamid- gruppen |
| UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US20020055631A1 (en) | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| CZ20033296A3 (cs) * | 2001-06-06 | 2004-04-14 | Eli Lilly And Company | Benzoylsulfonamidy a sulfonylbenzamidiny jako protinádorové sloučeniny |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| KR20100090726A (ko) | 2002-02-26 | 2010-08-16 | 아스트라제네카 아베 | 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물 |
| ES2342660T3 (es) | 2002-02-26 | 2010-07-12 | Astrazeneca Ab | Nuevas formas cristalinas del compuesto anticancerigeno zd1839. |
| FR2836914B1 (fr) | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| MY129850A (en) | 2002-04-29 | 2007-05-31 | Merck Sharp & Dohme | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| WO2005024636A1 (ja) | 2003-09-04 | 2005-03-17 | Hitachi Ulsi Systems Co., Ltd. | 半導体装置 |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7790190B2 (en) | 2004-03-20 | 2010-09-07 | Yasoo Health, Inc. | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
| WO2005099353A2 (en) | 2004-04-19 | 2005-10-27 | Symed Labs Limited | A novel process for the preparation of linezolid and related compounds |
| EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
| WO2006026501A1 (en) | 2004-08-27 | 2006-03-09 | Bayer Pharmaceuticals Corporation | New pharmaceutical compositions for the treatment of cancer |
| WO2006039164A2 (en) | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Novel cyclosporin analogues and their pharmaceutical uses |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| EP1888550B1 (en) | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Apoptosis promoters |
| DE602006014540D1 (en) | 2005-05-16 | 2010-07-08 | Irm Llc | Pyrrolopyridinderivate als proteinkinaseinhibitoren |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| CN102206216B (zh) | 2005-06-22 | 2014-11-12 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| EP1880715A1 (en) | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
| CA2662320C (en) | 2006-09-05 | 2014-07-22 | Abbott Laboratories | Bcl inhibitors treating platelet excess |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| WO2008064116A2 (en) | 2006-11-16 | 2008-05-29 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| CA2676944C (en) | 2007-02-15 | 2016-01-19 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
| WO2008124878A1 (en) | 2007-04-13 | 2008-10-23 | Cryptopharma Pty Ltd | Non-steroidal compounds |
| JP2010524972A (ja) | 2007-04-19 | 2010-07-22 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化したモルホリニル化合物 |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| AU2008307565A1 (en) | 2007-10-01 | 2009-04-09 | The Johns Hopkins University | Methods of treating neurological autoimmune disorders with cyclophosphamide |
| EP2209774A1 (en) | 2007-10-02 | 2010-07-28 | Concert Pharmaceuticals Inc. | Pyrimidinedione derivatives |
| WO2009051782A1 (en) | 2007-10-18 | 2009-04-23 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| AU2008317375B2 (en) | 2007-10-26 | 2013-02-28 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| EP2231159A1 (en) | 2007-11-16 | 2010-09-29 | Abbott Laboratories | Method of treating arthritis |
| JP2011506338A (ja) | 2007-12-06 | 2011-03-03 | アボット・ラボラトリーズ | 癌の治療のためのａｂｔ−２６３の経口用組成物 |
| US8187836B2 (en) | 2008-01-15 | 2012-05-29 | Abbott Laboratories | Mammalian expression vectors and uses thereof |
| ES2598178T5 (es) | 2008-10-07 | 2023-12-26 | Kudos Pharm Ltd | Formulación farmacéutica 514 |
| UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| HUE029289T2 (en) | 2008-12-05 | 2017-02-28 | Abbvie Inc | Sulfonamide derivatives as Bcl-2 selective apoptosis inducers for the treatment of cancer and immune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US20110245156A1 (en) | 2008-12-09 | 2011-10-06 | Cytokine Pharmasciences, Inc. | Novel antiviral compounds, compositions, and methods of use |
| WO2010072734A2 (en) | 2008-12-23 | 2010-07-01 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Targeting prodrugs and compositions for the treatment of gastrointestinal diseases |
| CN102282129A (zh) | 2009-01-19 | 2011-12-14 | 雅培制药有限公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| CN102282128B (zh) | 2009-01-19 | 2015-06-17 | Abbvie公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| US20100297194A1 (en) | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| NZ595708A (en) * | 2009-05-26 | 2014-03-28 | Abbvie Bahamas Ltd | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20100302253A1 (en) | 2009-05-29 | 2010-12-02 | Microsoft Corporation | Real time retargeting of skeletal data to game avatar |
| TWI540132B (zh) | 2009-06-08 | 2016-07-01 | 亞培公司 | Ｂｃｌ-２族群抑制劑之口服醫藥劑型 |
| CA3152557A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| TWI620736B (zh) | 2010-11-23 | 2018-04-11 | 艾伯維巴哈馬有限公司 | 使用選擇性ｂｃｌ-２抑制劑之治療方法 |
| PT2643322T (pt) * | 2010-11-23 | 2017-11-13 | Abbvie Inc | Sais e formas cristalinas de um agente indutor de apoptose |
-
2011
- 2011-11-21 PT PT117914010T patent/PT2643322T/pt unknown
- 2011-11-21 NO NO11791401A patent/NO2643322T3/no unknown
- 2011-11-21 EP EP11791401.0A patent/EP2643322B1/en not_active Revoked
- 2011-11-21 HU HUE11791401A patent/HUE034804T2/en unknown
- 2011-11-21 SI SI201131357T patent/SI2643322T1/en unknown
- 2011-11-21 BR BR112013012740A patent/BR112013012740A2/pt not_active Application Discontinuation
- 2011-11-21 JP JP2013540996A patent/JP6141188B2/ja active Active
- 2011-11-21 LT LTEP11791401.0T patent/LT2643322T/lt unknown
- 2011-11-21 SG SG2013039201A patent/SG190361A1/en unknown
- 2011-11-21 US US13/301,257 patent/US8722657B2/en active Active
- 2011-11-21 DK DK11791401.0T patent/DK2643322T3/en active
- 2011-11-21 AU AU2011332043A patent/AU2011332043C1/en active Active
- 2011-11-21 CN CN201710418588.6A patent/CN107266435A/zh active Pending
- 2011-11-21 ES ES11791401.0T patent/ES2644230T3/es active Active
- 2011-11-21 NZ NZ610151A patent/NZ610151A/en unknown
- 2011-11-21 KR KR1020137016317A patent/KR101923364B1/ko active Active
- 2011-11-21 RU RU2013128612A patent/RU2628560C2/ru active
- 2011-11-21 CN CN2011800657427A patent/CN103328474A/zh active Pending
- 2011-11-21 WO PCT/US2011/061678 patent/WO2012071336A1/en not_active Ceased
- 2011-11-21 PL PL11791401T patent/PL2643322T3/pl unknown
- 2011-11-21 MX MX2013005851A patent/MX343014B/es active IP Right Grant
- 2011-11-21 HR HRP20171754TT patent/HRP20171754T1/hr unknown
- 2011-11-21 CA CA2817629A patent/CA2817629C/en active Active
- 2011-11-21 RS RS20171232A patent/RS56697B1/sr unknown
- 2011-11-23 TW TW100142976A patent/TWI526443B/zh active
-
2013
- 2013-05-16 ZA ZA2013/03586A patent/ZA201303586B/en unknown
- 2013-05-21 IL IL226489A patent/IL226489B/en active IP Right Grant
-
2014
- 2014-03-27 US US14/228,132 patent/US9238649B2/en active Active
-
2015
- 2015-12-02 US US14/957,097 patent/US9840502B2/en active Active
-
2017
- 2017-11-08 US US15/806,964 patent/US10730873B2/en active Active
- 2017-11-17 CY CY20171101210T patent/CY1119648T1/el unknown
-
2019
- 2019-02-28 US US16/288,324 patent/US20190194196A1/en not_active Abandoned
-
2020
- 2020-04-08 US US16/843,729 patent/US20200231593A1/en not_active Abandoned
- 2020-04-24 US US16/858,278 patent/US20200255425A1/en not_active Abandoned
- 2020-07-31 US US16/944,265 patent/US20200361932A1/en not_active Abandoned
-
2022
- 2022-10-18 US US18/047,408 patent/US20230312566A1/en not_active Abandoned
-
2024
- 2024-12-13 US US18/980,589 patent/US20250340550A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119648T1 (el) | Αλατα και κρυσταλλικες μορφες παραγοντα που προκαλει αποπτωση | |
| UA113157C2 (xx) | Спосіб лікування з використанням селективних інгібіторів bcl-2 | |
| RU2014132884A (ru) | Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний | |
| NZ603463A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| CY1119066T1 (el) | Αναστολεις κρυσταλλικης βρωμο-περιοχης | |
| NZ607794A (en) | N-acylsulfonamide apoptosis promoters | |
| NZ703941A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| JP2013543896A5 (https=) | ||
| CY1117978T1 (el) | Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1a | |
| BR112012006252A2 (pt) | "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2". | |
| IL229199A (en) | N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs | |
| DOP2012000153A (es) | Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cancer y enfermedades inmunes | |
| UA112317C2 (uk) | Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину | |
| EA201001368A1 (ru) | Гетероциклические производные мочевины и способы их применения-211 | |
| EA200900638A1 (ru) | СОЛИ И КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 2-МЕТИЛ-2-[4-(3-МЕТИЛ-2-ОКСО-8-ХИНОЛИН-3-ИЛ-2,3-ДИГИДРОИМИДАЗО[4,5-c]ХИНОЛИН-1-ИЛ)ФЕНИЛ]ПРОПИОНИТРИЛА | |
| HK1212240A1 (en) | Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor | |
| NO20081482L (no) | Delta- og epsilon-krystallformer for imatinibmesylat | |
| DOP2012000298A (es) | Compuestos inductores de la apoptosis derivados de sulfonil carbamoil-fenoxi pirrolopiridina, útiles en el tratamiento del cancer y de enfermedades inmunes y autoinmunes | |
| NO20071593L (no) | Pyrimidinderivater | |
| NZ593594A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| MX2011012344A (es) | Sales de disacarina, acido difumarico, acido di-1-hidroxi-2-naftoi co y acido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino) butilo. | |
| MX2011011511A (es) | Sal de abt-263 y fomas en estado solido de la misma. | |
| MX374541B (es) | Sales de clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino) pirimidin-4-il)benzamida. | |
| BR112017004673A2 (pt) | formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida | |
| MX391445B (es) | Formas cristalinas de 3-(imidazol[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |